NCT06617286 - CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2039

Study Completion Date

December 31, 2040

Conditions

Classical Hodgkin Lymphoma

Interventions

BIOLOGICAL

CD30 CAR T-cell

After MAC and AutoHSCT patients will receive CD30+ CAR T-cells (Phase 1B dose level 1 - 1x108/m2 (max 2.5x108) or dose level 2 - 2x108/m2 (max 5.0 x108) 21-42 days after the AutoHSCT and the RP2D dose level obtained in the Phase IB part administered in the Phase II portion.

Trial Locations (1)

10595

New York Medical College, Valhalla